The first 5 pages, shown as text so search engines and readers can find this document.
Page 1
Mitochondrial dysfunction in pathophysiology
of heart failure
Bo Zhou, Rong Tian
J Clin Invest. 2018;128(9):3716-3726. https://doi.org/10.1172/JCI120849.
Mitochondrial dysfunction has been implicated in the development of heart failure. Oxidative
metabolism in mitochondria is the main energy source of the heart, and the inability to
generate and transfer energy has long been considered the primary mechanism linking
mitochondrial dysfunction and contractile failure. However, the role of mitochondria in heart
failure is now increasingly recognized to be beyond that of a failed power plant. In this
Review, we summarize recent evidence demonstrating vicious cycles of pathophysiological
mechanisms during the pathological remodeling of the heart that drive mitochondrial
contributions from being compensatory to being a suicide mission. These mechanisms
include bottlenecks of metabolic flux, redox imbalance, protein modification, ROS-induced
ROS generation, impaired mitochondrial Ca2+ homeostasis, and inflammation. The
interpretation of these findings will lead us to novel avenues for disease mechanisms and
therapy.
Review Series
Find the latest version:
http://jci.me/120849/pdf
Page 2
The Journal of Clinical Investigation
3 7 1 6 jci.org Volume 128 Number 9 September 2018R E V I E W S E R I E S : M I T O C H O N D R I A L D Y S F U N C T I O N I N D I S E A S E
Series Editor: Michael Sack
The heart is an organ with high energy demands. The majority of
the ATP consumed by the heart (~95%) is derived from oxidative
metabolism in the mitochondria, organelles that occupy approxi-
mately one-third of the volume of adult cardiomyocytes and are
colloquially known as the “powerhouses” of the cell. Mitochon-
drial dysfunction has been widely observed in the failing heart
irrespective of etiology. Although this dysfunction is recognized
as a maladaptive response, specific mechanisms connecting mito-
chondrial dysfunction and the development or progression of
heart failure are complex and are not fully understood. Initially,
decreased energy supply is considered the main consequence of
mitochondrial dysfunction. However, recent advances have iden-
tified a number of mechanisms that contribute to the pathogen-
esis of heart failure beyond the notion of “power plant” failure.
Here we will review some of the development in this area with an
emphasis on the crosstalk between impaired bioenergetics and the
maladaptive signaling circuit triggered by mitochondrial dysfunc-
tion in the pathophysiology of heart failure.
Overview of mitochondrial function
Mitochondria are double-membraned organelles found in nearly
all eukaryotic cells. A primary function of the mitochondrion is
to generate ATP through oxidative phosphorylation. Oxidative
phosphorylation takes place in the inner mitochondrial mem-
brane, during which reducing equivalents, e.g., NADH and
FADH2, are transferred from the carrier molecules to the elec-
tron transport chain (ETC) while protons are pumped to the
intermembrane space. Because the inner mitochondrial mem-
brane is impermeable to most ions and small molecules, proton
pumping generates a membrane potential that is used to convert
ADP to ATP by the ATP synthase. Thus, the inner membrane
impermeability and the mitochondrial membrane potential are
critical properties of functioning mitochondria.
To maintain oxidative phosphorylation, a variety of carbon
substrates are metabolized via specific pathways that eventually
converge on the tricarboxylic acid (TCA) cycle to produce reduced
equivalents, e.g., NADH and FADH2. Oxidative phosphorylation
also generates reactive oxygen species (ROS), which were first
considered by-products but were later found to possess many
(patho)physiological functions (Figure 1). Moreover, oxidative
metabolism in the mitochondria is not limited to ATP generation.
In certain cell types, such as brown adipocytes, uncoupling pro-
teins use the mitochondrial membrane potential for thermogen-
esis (1). Intermediary metabolism in the mitochondria provides
metabolites for multiple biological processes, such as biosynthesis
and protein modifications (refs. 2, 3, and Figure 1). Furthermore,
mitochondria regulate cell signaling by modulating redox state,
supplying cofactors for biochemical reactions and generating
ligands for signaling transduction (4–6).
Mitochondria possess active calcium transport systems, and
multiple enzymes in the oxidative metabolism pathways are acti-
vated by calcium. Thus, calcium is an important second messen-
ger connecting contractile function and mitochondrial metabo-
lism (7–11). Moreover, mitochondrial uptake of calcium has been
proposed as a mechanism that maintains intracellular calcium
homeostasis (12). The identification of mitochondrial calcium uni-
porter (MCU) in 2011 (13, 14) stimulated an array of investigations
on the role of mitochondrial calcium in health and diseases.
The roles of mitochondria are not limited to supporting life;
rather, they are also actively involved in initiating cell death. Stress
conditions that lead to calcium or ROS overload trigger the open-
ing of the mitochondrial permeability transition pore (mPTP),
leading to loss of mitochondrial membrane potential (15–18). This
results in failure to produce ATP and release of mitochondrial
proteins such as cytochrome c, which trigger cell death through
necrotic and apoptotic pathways, respectively (refs. 16, 17, 19, and
Mitochondrial dysfunction has been implicated in the development of heart failure. Oxidative metabolism in mitochondria
is the main energy source of the heart, and the inability to generate and transfer energy has long been considered the
primary mechanism linking mitochondrial dysfunction and contractile failure. However, the role of mitochondria in heart
failure is now increasingly recognized to be beyond that of a failed power plant. In this Review, we summarize recent
evidence demonstrating vicious cycles of pathophysiological mechanisms during the pathological remodeling of the
heart that drive mitochondrial contributions from being compensatory to being a suicide mission. These mechanisms
include bottlenecks of metabolic flux, redox imbalance, protein modification, ROS-induced ROS generation, impaired
mitochondrial Ca2+ homeostasis, and inflammation. The interpretation of these findings will lead us to novel avenues for
disease mechanisms and therapy.
Mitochondrial dysfunction in pathophysiology
of heart failure
Bo Zhou and Rong Tian
Mitochondria and Metabolism Center, University of Washington, Seattle, Washington, USA.
Conflict of interest: The authors have declared that no conflict of interest exists.
Reference information: J Clin Invest. 2018;128(9):3716–3726.
https://doi.org/10.1172/JCI120849.
Page 3
The Journal of Clinical InvestigationR E V I E W S E R I E S : M I T O C H O N D R I A L D Y S F U N C T I O N I N D I S E A S E
3 7 1 7jci.org Volume 128 Number 9 September 2018
oxidation is downregulated (29). Notably, ATP generated from
glycolysis alone contributes less than 5% of the total ATP con-
sumed in a normal adult heart (29). Thus, upregulating glycolysis
is not an effective method of increasing energy supply.
On the energy demand side, pathological remodeling increas-
es energy expenditure through unfavorable cardiac geometry,
increased neurohormonal stimulation, and impaired calcium han-
dling (30, 31). Collectively, these changes disturb the homeostasis
between energy supply and demand, resulting in a stress on myo-
cardial energetics (Figure 2). The hypothesis that a failing heart is
energy starved is consistent with such a scenario and has inspired
decades of research to date (refs. 28, 32–34). Clinical evidence
supporting the energy starvation hypothesis in heart failure comes
from the observation that therapeutic measures to reduce energy
consumption, such as vasodilators and beta blockers, improve
survival in heart failure, while treatments that increase energy
demand of the heart, such as inotropes, worsen the outcome (refs.
35–37 and Figure 2). Few strategies of increasing ATP supply have
been tried clinically thus far (38, 39).
The high-energy phosphate content of the failing heart is
reduced. This is first manifested as a decrease of the energy
reserve compound phosphocreatine (PCr) resulting in a lower
PCr/ATP ratio (40–43). It is puzzling, however, that the ATP con-
tent in a failing heart is largely maintained until the end stage
(40, 42–45) despite the early signs of a mismatch between energy
supply and demand. One interpretation of this observation is that
myocardial energy status is sustained by “adaptive” mechanisms
mobilized during the progression of heart failure (46, 47). The
nature of these mechanisms is poorly understood. Whether they
are ultimately adaptive warrants reevaluation. As the stressed
heart goes on a downward spiral to failure despite a relatively sta-
ble ATP level, it raises a possibility that mechanisms used during
cardiac remodeling to restore energy homeostasis, which are
either originating from or targeted to mitochondria, contribute
to the vicious cycles that drive cardiac remodeling to heart failure
(Figure 2). This leads to the question of whether the demise of the
stressed heart is caused by energy starvation or the effort to fight
starvation. In sections below, recent studies examining the meta-
bolic and/or mitochondrial responses in the chronically stressed
heart are reviewed to determine whether efforts to sustain energy
homeostasis can be potentially costly to the failing heart and thus
accelerate heart failure. These areas are also potential therapeutic
opportunities (Figure 2).
Bottleneck of metabolic flux in heart failure
Cardiomyocytes possess a high capacity for oxidative metabolism
and are capable of using a variety of carbon substrates for ATP
synthesis. In a normal heart, the flux through intermediate metab-
olism and oxidative phosphorylation can increase substantially
to meet energy demand during high-performance activities such
as exercise (48, 49). The heart is also metabolically flexible, able
to adapt to fuel availability by switching its substrate preference
(27). If this is the case, what are the bottlenecks that render failing
hearts incapable of using these mechanisms to maintain energy
homeostasis during chronic stress?
A hallmark of metabolic remodeling in pathological hypertro-
phy is downregulation of fatty acid oxidation and increased utiliza-
Figure 1). It has been shown that mitochondria-initiated cell death
is an important mechanism in heart failure (20), and the links
between mitochondrial calcium content and cardiac dysfunction
during chronic stress have been a focus of investigation over the
past decade. Mitochondrial DNA and/or ROS have been shown
to be triggers of inflammatory response (21–24). Regulation of
innate immunity by mitochondrial function has been increasing-
ly recognized in both cardiac and noncardiac diseases (21–25). As
sterile inflammation is common in heart failure, the role of mito-
chondrial function has also emerged as an important pathogenic
mechanism, which will be discussed in detail below. Collectively,
these observations suggest that molecular mechanisms promoting
the transition of mitochondria from energy-producing to death-
initiating functions (Figure 1) are key to identifying disease mech-
anisms and therapeutic targets.
Mitochondrial dysfunction and energy starvation
in heart failure
If ATP synthesis were ceased in a healthy human heart, stored ATP
would sustain heartbeat for only a few seconds (26). It is therefore
essential that the rate of ATP consumption is matched with the
rate of ATP synthesis on a beat-to-beat basis. This is accomplished
by oxidative metabolism in mitochondria using fatty acids as the
primary fuel (27, 28). During pathological heart remodeling, car-
diac metabolism is reprogrammed toward increased reliance on
glucose with a significant increase of glycolysis, whereas fatty acid
Figure 1. An overview of mitochondrial function in health and disease.
Mitochondria are known as the powerhouse of the cell. Under normal
conditions, oxidative metabolism in mitochondria produces ATP; it also
produces heat in certain specialized cell types, such as brown adipocytes.
In addition to generating ATP, intermediate metabolism in the mitochon-
dria produces metabolites for biosynthesis, protein modification, and
signal transduction. Oxidative phosphorylation is coupled with genera-
tion of reactive oxygen species (ROS), which can either serve as molecular
signals or cause cell damage and cell death. Mitochondrial metabolism is
stimulated by calcium, but under pathological conditions, calcium over-
load can trigger the opening of the mitochondrial permeability transition
pore (mPTP). The release of mitochondrial content, such as cytochrome c,
induces apoptosis, or the loss of membrane potential (a consequence of
prolonged mPTP opening) causes ATP deprivation and necrosis. Leak of
damage-associated molecular patterns (DAMPs), such as mitochondrial
DNA and peptides, or excessive ROS generation also causes inflamma-
tion that results in further tissue damage. The transition of mitochondria
from a powerhouse to a death engine is key to the pathogenesis of many
diseases, including heart failure (also see Figure 3).
Page 4
The Journal of Clinical InvestigationR E V I E W S E R I E S : M I T O C H O N D R I A L D Y S F U N C T I O N I N D I S E A S E
3 7 1 8 jci.org Volume 128 Number 9 September 2018
phy prevents increased reliance on glucose and thus suppresses
the effects of glucose on pathological growth (58, 61). Inability to
oxidize fatty acids under conditions of increased lipid availability,
such as obesity and diabetes, could lead to accumulation of lipotox-
ic metabolites (62). Moreover, incomplete fatty acid oxidation has
been implicated in the development of insulin resistance in skeletal
muscle, although similar studies in the heart are lacking (63, 64).
More recently, it was observed that ketone body oxidation
was increased in the failing hearts of both human and animal
models (65, 66). This increase is associated with elevated circu-
lating ketone levels in patients with heart failure (65, 67), sug-
gesting a change in systemic metabolism. While emerging work
suggests that increased ketone body oxidation is cardioprotective
(68), its underlying mechanisms remain to be elucidated. Besides
providing energy to compensate for reduced fatty acid oxidation,
other potential mechanisms have been proposed as benefits of
increased ketone body utilization, including modulation of oxi-
dative stress and posttranslational modifications (68–70). Fur-
thermore, oxidation of fatty acids or ketone body reduces glucose
use by the heart (58, 71, 72); thus, the benefit of increasing ketone
body utilization in the failing heart could also be attributed to
reduced reliance on glucose.
Mitochondrial oxidation reduction and protein
modification
Mitochondrial proteins can be modified through acylation of
lysine residues by thioester-CoAs, such as acetyl-CoA, succinyl-
CoA, malonyl-CoA, etc., produced by intermediary metabolism
(73). The most studied modification is acetylation, although
modifications by other acyl-CoAs also occur in the mitochondria
(Figure 3). Increased mitochondrial protein acetylation has been
found in the failing hearts of animal models and patients (74–78).
A large number of proteins, including those involved in substrate
oxidation, e.g., pyruvate dehydrogenase and fatty acid oxida-
tion of glucose. Prior studies showed that a greater reliance on glu-
cose in the failing heart led to increased glycolysis that had been
uncoupled from oxidation, causing increases in lactate production
and anaplerosis (29, 50). It also drives a greater flux of glucose into
accessory pathways, all of which reduce the efficiency of ATP syn-
thesis and exacerbate pathological remodeling (27, 29, 50). Pro-
moting glucose oxidation, either directly or by inhibiting fatty acid
oxidation, has been proposed as a therapeutic strategy (28, 51).
Partly replacing fatty acids by glucose for energy provision was
considered beneficial because ATP generation from glucose could
moderately increase oxygen efficiency (52, 53). However, the
capacity for glucose-derived ATP production is rather limited in
adult hearts (27). Increased glucose uptake and metabolism also
enables growth signaling that promotes the pathological remod-
eling of the heart. A recent study showed that high intracellular
glucose inhibits branched-chain amino acid (BCAA) catabolism,
resulting in BCAA accumulation during the development of car-
diac hypertrophy (54). Such a metabolic response is required for
mTOR activation and cardiomyocyte hypertrophy. These findings
imply that shifts in substrate preference to glucose support growth
at the cost of contractile performance. In support of this notion,
enhancing glucose uptake capacity to a superphysiological level
was shown to improve myocardial energetics as well as stimulate
pathological hypertrophy (55, 56).
Fatty acid is the predominant fuel for the adult heart. Its long
carbon chain makes fatty acid the most effective substrate for ener-
gy provision. Downregulation of fatty acid oxidation pathways and
accumulation of incompletely oxidized fatty acids were observed
in an early stage of heart failure, suggesting a mismatch between
fatty acid supply and oxidation (57). Promoting fatty acid utili-
zation has been shown to be beneficial in a number of models of
heart failure (58–60). However, the benefit of sustaining fatty acid
oxidation is likely beyond energy supply. Recent evidence suggests
that sustaining fatty acid oxidation during pathological hypertro-
Figure 2. Mismatch of energy demand and generation drives the development of heart failure. In a healthy heart, energy production meets energy
demand on a beat-by-beat basis. Pathological remodeling of the heart results in inefficiencies that increase energy demand but concomitantly reduce the
capacity for energy supply. The subsequent metabolic remodeling in an attempt to regain energy homeostasis temporarily sustains the ATP level in the
heart but likely drives the heart to failure via maladaptive circuits that produce mitochondrial stress. Current heart failure therapy aims at reducing the
energy demand to alleviate the mismatch. Strategies that antagonize metabolic remodeling and/or mitochondrial stress signaling cascade could offer
novel therapies. FAO, fatty acid oxidation.
Page 5
The Journal of Clinical InvestigationR E V I E W S E R I E S : M I T O C H O N D R I A L D Y S F U N C T I O N I N D I S E A S E
3 7 1 9jci.org Volume 128 Number 9 September 2018
fatty acid oxidation in failing hearts is associated with an increased
level of short-chain acyl-CoAs in the myocardium (57, 66); thus, a
mismatch in the supply and oxidation of acetyl-CoA may lead to
increased protein acetylation (Figure 3).
Another potential mechanism of protein hyperacetylation is
reduced protein deacetylation, which is catalyzed by the sirtuin
family of NAD+-dependent deacetylases (Figure 3). Three sirtu-
in proteins are localized to the mitochondria: SIRT3, SIRT4, and
SIRT5, among which SIRT3 is the predominant deacetylase (73).
SIRT4 and SIRT5 have weak deacetylase function but possess
demalonylase and desuccinylase activities or ADP-ribosylation
function (73). Downregulation of SIRT3 has been shown in the
failing heart (78, 85). Furthermore, sirtuin activity is dependent
on NAD+ availability. Diminished NAD+ level and reduced NAD+/
NADH ratio have been observed in hearts with mitochondrial
dysfunction and/or pathological hypertrophy (75, 86, 87). A low-
er NAD+/NADH ratio decreases enzymatic activities for substrate
tion enzymes, TCA cycle enzymes, and ETC proteins, have been
shown to be hyperacetylated (75, 76). Protein hyperacetylation has
been shown to decrease activities of succinate dehydrogenase,
pyruvate dehydrogenase, ATP synthase, and malate-aspartate
shuttle enzymes; additionally, hyperacetylation of oligomycin
sensitivity–conferring protein (OSCP) increased the sensitivity
to mPTP opening (75, 76, 78–82). Moreover, inhibition of malate-
aspartate shuttle by acetylation impairs the transport of cytosolic
NADH into mitochondria, thereby disrupting cytosolic redox state
and glycolytic ATP production during the transition from cardiac
hypertrophy to failure (76, 83).
The cause of mitochondrial protein hyperacetylation in the
failing heart is less understood. One possibility is the presence of
excessive acyl-CoAs. It has been shown that protein acylation can
either be mediated by an acyltransferase or occur nonenzymati-
cally (73, 84), and in the latter case, the concentration of the acyl-
CoAs is an important determinant of the modification. Reduced
Figure 3. Maladaptive mechanisms connecting mitochondrial dysfunction and progression of heart failure. Inadequate stimulation of mitochondrial
metabolism increases ATP generation at the expense of triggering maladaptive responses such as imbalance among substrate supply, catabolism, and
oxidative phosphorylation (OXPHOS), as well as increased protein modifications by acylation such as acetylation (LysAc). Increased availability of acyl-CoA
is a driver for protein modification, while the mismatch between NADH production and oxidation decreases the NAD+/NADH ratio, compromising the sirtuin
deacetylase function. These effects collectively increase protein acetylation in the failing heart. Increased protein acylation, especially acetylation, impairs
energy metabolism through negative feedback to substrate metabolism and OXPHOS. Further stimulation of mitochondrial metabolism under these condi-
tions increases the risk of calcium overload, leads to greater ROS generation, and induces mPTP opening. Increased protein acetylation also weakens antiox-
idant defense and sensitizes the mPTP to calcium or ROS. In the face of increased oxidative stress, effort to maintain the mitochondrial antioxidant system
(e.g., the Gpx or Prx pathway) may divert energy metabolism away from ATP generation through nicotinamide nucleotide transhydrogenase (Nnt). Oxidative
damage causes ROS-induced ROS release, leading to further injury of mitochondria. Failure to remove the damaged mitochondria results in the leak of
DAMPs, such as mitochondrial DNA or peptides, that trigger an inflammatory response. NAD+/NADH redox imbalance also promotes NLRP3 inflammasome
activation. The vicious cycle of these mechanisms ultimately drives mitochondria from being energy-producing to death-initiating organelles.